Idenix Achieves $20M Milestone in HIV Deal with ViiV Healthcare
Idenix Pharmaceuticals will receive $20 million from ViiV Healthcare for the achievement of a clinical milestone relating to GSK2248761.
Idenix Pharmaceuticals will receive $20 million from ViiV Healthcare for the achievement of a clinical milestone relating to GSK2248761 (known as '761). ViiV is testing the compound in a Phase IIb trial as a treatment of HIV/AIDS.
In February 2009, GlaxoSmithKline (GSK) paid Idenix $34 million for a worldwide license to '761, a non-nucleoside reverse transcriptase inhibitor (NNRTI) for HIV/AIDS. In November 2009, GSK and Pfizer created ViiV Healthcare, an independent company focused solely on research, development, and commercialization of HIV medicines.
Idenix says that it has received approximately $60 million in total collaboration-related payments. The firm could earn another $390 million in milestone fees as well as double-digit tiered royalties on worldwide product sales.
ViiV was seeded with 10 approved products from GSK and Pfizer and has five developmental candidates. 1349572 and S/GSK 1265744 are integrase inhibitors in Phase III, UK-453061 is an NN
Related News
-
.png)
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
.png)
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
.png)
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
.png)
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
.png)
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance